Pzena Investment Management LLC Raises Stock Holdings in USANA Health Sciences, Inc. (NYSE:USNA)

Pzena Investment Management LLC raised its stake in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 3.6% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,087,076 shares of the company's stock after purchasing an additional 37,466 shares during the period. Pzena Investment Management LLC owned 5.70% of USANA Health Sciences worth $39,015,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. R Squared Ltd bought a new stake in USANA Health Sciences during the fourth quarter valued at about $28,000. Safe Harbor Fiduciary LLC bought a new position in shares of USANA Health Sciences in the third quarter worth about $30,000. KBC Group NV boosted its stake in shares of USANA Health Sciences by 96.6% in the third quarter. KBC Group NV now owns 1,056 shares of the company's stock worth $40,000 after acquiring an additional 519 shares during the period. Amundi boosted its stake in shares of USANA Health Sciences by 85.3% in the fourth quarter. Amundi now owns 4,872 shares of the company's stock worth $170,000 after acquiring an additional 2,243 shares during the period. Finally, Centiva Capital LP bought a new position in shares of USANA Health Sciences in the third quarter worth about $213,000. Institutional investors own 54.25% of the company's stock.

USANA Health Sciences Stock Performance

USNA stock traded down $1.34 during midday trading on Friday, reaching $29.04. 229,896 shares of the company traded hands, compared to its average volume of 101,810. USANA Health Sciences, Inc. has a 52-week low of $27.71 and a 52-week high of $50.32. The business has a 50 day moving average of $32.67 and a 200-day moving average of $36.01. The firm has a market capitalization of $553.41 million, a price-to-earnings ratio of 10.26, a P/E/G ratio of 0.93 and a beta of 0.98.

Remove Ads

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The firm had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million. Research analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. DA Davidson dropped their price objective on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, February 27th. Sidoti lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th. Finally, StockNews.com lowered USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th.

Insiders Place Their Bets

In other USANA Health Sciences news, CEO Jim Brown sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $29.47, for a total transaction of $147,350.00. Following the sale, the chief executive officer now owns 15,716 shares of the company's stock, valued at approximately $463,150.52. This trade represents a 24.14 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Mulham Mulham sold 3,234 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $32.98, for a total value of $106,657.32. Following the sale, the insider now directly owns 12,775 shares in the company, valued at $421,319.50. This trade represents a 20.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 15,920 shares of company stock worth $500,285 in the last ninety days. 0.33% of the stock is owned by company insiders.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.